This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.

This is a study evaluating whether the use of an electronic web-based tool containing surveys could support patients and doctors make better treatment decisions together. New patients, 60 years or older, will be randomized to either receive the tool or not. Surveys will be collected from patients about their experience in making treatment decisions to evaluate whether the tool was beneficial.

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

To create digital tools to support young adult cancer survivors completing active treatment and transitioning into survivorship care.

The purpose of this study is to create a registry that will collect clinical data from participants attending UNC Hospitals who may present with metastatic cancer and are evaluated to receive radiation therapy. We hope to create a registry that future studies can pull from to study the impacts of radiation therapy on patient cancer outcomes.

This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.

The purpose of this study is to identify specific barriers to preventing a late stage cancer diagnosis within communities identified in North Carolina as having a higher rate of advanced cancer diagnoses.

Collecting data on chronic GVHD instances

Cancer is the leading cause of death in the Hispanic population in the U.S. Our study focuses on collecting information to build a cancer registry from a diverse Hispanic population to identify specific cultural and demographic details that will allow us to determine which attribute carries a higher risk of a poor outcome. We will also be utilizing a set of questionnaires and surveys that evaluate the health and functionality of older adults thoroughly and efficiently. These surveys provide a wealth of prognostic data and have been shown to detect deficits even in younger patients. Although the information we hope to collect is of considerable value, we must first examine whether our approach to consenting patients and having them complete these questionnaires is feasible. We anticipate that the findings from our study will provide valuable insights on Hispanic adults with cancer as a unique and growing patient population in the U.S.

No guidelines or interventions for patients and their family caregivers exist to support patient adherence to a new medication (venetoclax) and their quality of life. Our research team seeks to understand the real experience and care needs of patients and their family caregivers with the new AML treatment. With the information we learn from this study, we will be able to develop an effective support program for patients with AML and their family caregivers to manage their symptoms at home and improve their quality of life.